LIVE

CGON

CG Oncology Inc.

CGON

NASDAQ·Healthcare·Biotechnology·Mkt cap $6.3B

$69.64

▼ -1.76%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$23.65 - $77.00

P/E

-29.76

Fwd P/E

-26.67

Beta

0.31

Div Yield

0.00%

Avg Vol

1.1M

Shares Out

84.4M

Mkt Cap

$6.3B

Price action

Price chart

Up 165.7% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • First-mover advantage in BCG-unresponsive NMIBC treatment segment
  • Proprietary cretostimogene technology with bladder-sparing mechanism
  • Focused pipeline reducing development complexity and capital requirements
  • Large addressable market with significant unmet medical need
▼

Bear Case

1 risk

  • Low volatility (beta 0.3).

Growth

Strong growth ahead

Clinical trial progression and regulatory milestones for cretostimogene

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Strong

+5.0% over 3m

Quality

Loss-making

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 7, 2026

“
Q2 26 RECAP

MAY 8, 2026

Reported EPS of -$0.71 vs -$0.58 consensus (-22.4% surprise). Revenue of $1.1M vs $453.0K expected (+139.1%).

EPS miss
Rev beat +139.1%

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-22.4%

Next: May 7, 2026

Revenue trend · last 8Q

—

—

—

-90%

-100%

+3774%

+409%

+1983%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$111.0K

$43.0K

$456.0K

$52.0K

$0

$1.7M

$2.3M

$1.1M

Margins · last 8Q

Gross

—

Profit

-5558.8%

View full earnings history →

Wall Street consensus

6 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

6

100%

Hold

0%

Sell

0%

Median Price Target

$80.50

▲ +15.6% vs $69.64

Low $79.00
Median $80.50
High $82.00

Latest: HC Wainwright · May 18, 2026

3 analysts covering

View full analyst page →

vs Industry

How CGON stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.